Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | FT95N | — |
A female patient got the first dose back in 2022 and as of today (25 August 2025) she received the second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 86-year-old female patient who received Herpes zoster (Shingrix) (batch number FT95N, expiry date 25-APR-2027) for prophylaxis. Previously administered products included Shingrix (First dose was received back in 2022.). On 25-AUG-2025, the patient received the 2nd dose of Shingrix. On 25-AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: A female patient got the first dose back in 2022 and as of today (25 August 2025) she received the second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 25-AUG-2025 A pharmacist called to get guidance with the Shingrix vaccine series. A female patient got the first dose back in 2022 and as of today (25 August 2025) she received the second dose, which led to lengthening of vaccination schedule. The pharmacist called to know if the second dose could be counted or the patient has to restart the complete series again.